What is BNTC (BNTC) stock price today?

BNTC (BNTC) is currently trading at $13.07, down 0.46% today.

What is BNTC P/E ratio?

BNTC's P/E ratio is -11.78. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BNTC return on equity (ROE)?

BNTC's return on equity (ROE) is -33.50%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is BNTC's market cap?

BNTC has a market capitalization of $449.01M.

NCM · Biotechnology

BNTC (BNTC) Stock

$13.07 -0.46% NCM: BNTC Healthcare

Valuation

Metric	Value
Price	$13.07
Market Cap	$449.01M
P/E Ratio	-11.78
P/B Ratio	2.24
P/S Ratio	595.28
EPS (TTM)	$0.00
52-Week High	$16.76
52-Week Low	$9.85
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-33.50%
ROA	-22.40%
ROCE	-42.86%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	49.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-14.0M	$-18.0M	$-19.0M	$-23.0M	$-42.0M
Net Profit	$-14.0M	$-18.0M	$-20.0M	$-22.0M	$-38.0M
EPS	$-27.27	$-19.31	$-14.12	$-2.68	$-1.05
Op Margin	-23044.1%	-24457.5%	-25441.3%	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$21.0M	$6.0M	$4.0M	$52.0M	$100.0M
Total Liabilities	$1.0M	$3.0M	$4.0M	$5.0M	$2.0M
Cash	$20.0M	$4.0M	$2.0M	$51.0M	$98.0M
Borrowings	$0	$1.0M	$1.0M	$0	$1.0M

Latest News

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update GlobeNewswire · May 14, 2026 Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire · Apr 28, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-13.0M	$-16.0M	$-18.0M	$-19.0M	$-24.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$-3.0M	$0	$-2.0M	$-3.0M	$0
Net Cash Flow	$10.0M	$-16.0M	$-2.0M	$48.0M	$47.0M
Free Cash Flow	$-13.0M	$-16.0M	$-18.0M	$-20.0M	$-24.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-5.67%
Quick Ratio	67.69
Interest Coverage	—
Return 1Y	-3.46%
Return 3Y	218.93%
Return 5Y	-79.91%

Ownership

Insiders Held2.55%

Institutions Held98.31%

Institutions Float Held100.88%

Institutional Holder	Shares	Report Date
Suvretta Capital Management, LLC	11,548,351	2026-03-31
Janus Henderson Group PLC	2,876,380	2026-03-31
Franklin Resources, Inc.	2,378,159	2026-03-31
Adage Capital Partners GP L.L.C.	2,120,672	2026-03-31
RA Capital Management, L.P.	1,850,000	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AUTLAutolus Therapeutics plc	$1.46	-13.61%	-1.35	—	0.00%
GALTGalectin Therapeutics Inc.	$3.33	-4.18%	-8.53	$218.97M	0.00%
IMABI-Mab	$2.88	-0.69%	-59.63	$542.01M	0.00%
LCTX	$1.13	-0.88%	-17.61	$281.71M	0.00%
NGNE	$32.90	+0.03%	-5.25	$519.90M	0.00%

About BNTC

BNTC is led by CEO Jerel A. Banks, employs 16 people, headquartered in US, publicly traded since 2014.

BNTC stock trades at $13.07 with a market capitalization of $449.01M. The stock is valued at a price-to-earnings (P/E) ratio of -11.78, price-to-book of 2.24, price-to-sales of 595.28. Over the past 52 weeks the stock has ranged between $9.85 and $16.76, and currently trades 22.0% below its 52-week high.

On profitability, BNTC generates a return on equity (ROE) of -33.50%, return on capital employed of -42.86%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides